Drug Trial Radar · NCT04996797
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
178
Actual
Start
Jul 14, 2021
Primary completion
Jun 6, 2023
Study completion Jul 14, 2025
Sponsor
- Lead sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Aug 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with moderately to severely active Ulcerative Colitis (UC). After the completion of the 12-week induction, all participants have the option to continue in the open-label extension for up to 170 weeks.
Conditions
- Ulcerative Colitis
Interventions
TulisokibartDrug
Administered by IV infusion
Companion Diagnostic (CDx) TestingDevice
PRA023 CDx Genotyping Assay
PlaceboOther
Placebo administered by IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants in Cohort 1 Achieving Clinical RemissionTime frame: Baseline and Week 12
- Percentage of Participants Who Experienced an Adverse Event (AE)Time frame: Up to ~14 weeks
- Percentage of Participants Who Discontinued Due to an AETime frame: Up to ~14 weeks
- Percentage of Participants Who Had One or More Serious Adverse EventsTime frame: Up to ~14 weeks
Locations
88 sites in 12 countries. Site status is shown where the registry gives one.
Prometheus Biosciences Selected Center
Mobile, Alabama
Prometheus Biosciences Selected Site
Phoenix, Arizona
Prometheus Biosciences Selected Site
Sun City, Arizona
Prometheus Biosciences Selected Site
Los Angeles, California
Prometheus Biosciences Selected Site
Los Angeles, California
Prometheus Biosciences Selected Site
San Diego, California
Prometheus Biosciences Selected Site
Bristol, Connecticut
Prometheus Biosciences Selected Site
Atlanta, Georgia
Prometheus Biosciences Selected Site
Arlington Heights, Illinois
Prometheus Biosciences Selected Site
Glenview, Illinois
Prometheus Biosciences Selected Site
Gurnee, Illinois
Prometheus Biosciences Selected Site
Kansas City, Kansas
Prometheus Biosciences Selected Site
Liberty, Kansas
Prometheus Biosciences Selected Site
Baton Rouge, Louisiana
Prometheus Biosciences Selected Site
Chevy Chase, Maryland
Prometheus Biosciences Selected Site
Chesterfield, Michigan
Prometheus Biosciences Selected Site
Lebanon, New Hampshire
Prometheus Biosciences Selected Site
New York, New York
Prometheus Biosciences Selected Site
New York, New York
Prometheus Biosciences Selected Site
Dublin, Ohio
Prometheus Biosciences Selected Site
Germantown, Tennessee
Prometheus Biosciences Selected Site
Bedford, Texas
Prometheus Biosciences Selected Site
Lubbock, Texas
Prometheus Biosciences Selected Site
Mansfield, Texas
Prometheus Biosciences Selected Site
San Antonio, Texas
Prometheus Biosciences Selected Site
Southlake, Texas
Prometheus Biosciences Selected Site
Tyler, Texas
Prometheus Biosciences Selected Site
Charlottesville, Virginia
Prometheus Biosciences Selected Site
Tacoma, Washington
Prometheus Biosciences Selected Site
Woodville, Adelaide, Australia
Prometheus Biosciences Selected Site
Kingswood, New South Wales, Australia
Prometheus Biosciences Selected Site
Old Toongabbie, New South Wales, Australia
Prometheus Biosciences Selected Site
South Brisbane, Queensland, Australia
Prometheus Biosciences Selected Site
Woolloongabba, Queensland, Australia
Prometheus Biosciences Selected Site
Adelaide, South Australia, Australia
Prometheus Biosciences Selected Site
Fitzroy, Victoria, Australia
Prometheus Biosciences Selected Site
Melbourne, Victoria, Australia
Prometheus Biosciences Selected Site
Leuven, Belgium
Prometheus Biosciences Selected Site
Liège, Belgium
Prometheus Biosciences Selected Site
Calgary, Alberta, Canada
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.